Stock Analysis

July 2024 Insight: 3 SEHK Stocks Estimated To Be Trading Below Fair Value

SEHK:1382
Source: Shutterstock

Amidst a backdrop of global economic fluctuations and mixed performances in key markets, the Hong Kong stock market has shown resilience, with the Hang Seng Index posting modest gains. This stability presents an intriguing opportunity for investors to consider stocks that may be trading below their fair value, potentially offering attractive returns in a cautiously optimistic economic environment.

Top 10 Undervalued Stocks Based On Cash Flows In Hong Kong

NameCurrent PriceFair Value (Est)Discount (Est)
Giant Biogene Holding (SEHK:2367)HK$40.70HK$75.8346.3%
China Cinda Asset Management (SEHK:1359)HK$0.66HK$1.2948.8%
Super Hi International Holding (SEHK:9658)HK$13.92HK$26.0446.5%
Shanghai INT Medical Instruments (SEHK:1501)HK$26.45HK$48.2345.2%
Zhaojin Mining Industry (SEHK:1818)HK$14.98HK$29.8649.8%
BYD (SEHK:1211)HK$235.20HK$464.8349.4%
AK Medical Holdings (SEHK:1789)HK$4.34HK$7.9545.4%
Vobile Group (SEHK:3738)HK$1.20HK$2.3148.1%
MicroPort Scientific (SEHK:853)HK$5.16HK$9.4845.6%
Q Technology (Group) (SEHK:1478)HK$4.05HK$7.4545.7%

Click here to see the full list of 42 stocks from our Undervalued SEHK Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies

Pacific Textiles Holdings (SEHK:1382)

Overview: Pacific Textiles Holdings Limited is a company that manufactures and trades in textile products, with a market capitalization of approximately HK$2.34 billion.

Operations: The company generates its revenue primarily from the manufacturing and trading of textile products, totaling approximately HK$4.67 billion.

Estimated Discount To Fair Value: 38.3%

Pacific Textiles Holdings is currently trading below its fair value by 38.3% at HK$1.67, against a fair value estimate of HK$2.71, highlighting its potential undervaluation based on cash flows. Despite a significant decrease in net profit and a drop in sales from HK$5.02 billion to HK$4.67 billion year-over-year, the company's earnings are expected to grow by 37.7% annually, outpacing the Hong Kong market average growth of 11.3%. However, profit margins have declined and recent corporate governance updates aim to align with new regulatory standards.

SEHK:1382 Discounted Cash Flow as at Jul 2024
SEHK:1382 Discounted Cash Flow as at Jul 2024

Shanghai INT Medical Instruments (SEHK:1501)

Overview: Shanghai INT Medical Instruments Co., Ltd. operates in the healthcare sector, focusing on the development and manufacture of medical instruments, with a market capitalization of approximately HK$4.63 billion.

Operations: Shanghai INT Medical Instruments primarily generates revenue from its cardiovascular interventional business, totaling CN¥641.32 million.

Estimated Discount To Fair Value: 45.2%

Shanghai INT Medical Instruments is significantly undervalued based on DCF, with its current price of HK$26.45 sitting well below the estimated fair value of HK$48.23. The company's revenue and earnings are projected to grow at 26% and 25.4% per year respectively, outstripping the Hong Kong market averages significantly. Despite past shareholder dilution, recent dividend increases reflect a positive cash flow outlook, further underscoring its potential as an undervalued stock in Hong Kong’s market.

SEHK:1501 Discounted Cash Flow as at Jul 2024
SEHK:1501 Discounted Cash Flow as at Jul 2024

China International Capital (SEHK:3908)

Overview: China International Capital Corporation Limited operates as a financial services provider in Mainland China and globally, with a market capitalization of approximately HK$101.29 billion.

Operations: The company generates its revenues from various financial services both in Mainland China and internationally.

Estimated Discount To Fair Value: 13.4%

China International Capital Corporation Limited, trading at HK$8.19, is positioned below the estimated fair value of HK$9.46, suggesting a modest undervaluation based on discounted cash flow analysis. The company's revenue and earnings growth projections of 8.4% and 20.35% annually are poised to surpass Hong Kong market averages of 7.6% and 11.3%, respectively. However, its forecasted return on equity in three years at 6.9% remains low, indicating potential concerns about profitability efficiency despite positive growth metrics.

SEHK:3908 Discounted Cash Flow as at Jul 2024
SEHK:3908 Discounted Cash Flow as at Jul 2024

Turning Ideas Into Actions

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com